Long Non-Coding RNA BCAR4 Promotes Oxaliplatin Resistance in Colorectal Cancer by Modulating miR-484-3p/RAB5C Expression
Chemotherapy · 2023 · 68 (3) · 119-130
DOI: 10.1159/000529134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 19.01.2023. Verfasst von Xianting Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: MicroRNAs, RNA, Long Noncoding, Colorectal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Oxaliplatin-based chemotherapy resistance is a major cause of recurrence in patients with colorectal cancer (CRC). Increasing evidence indicates that lncRNA BCAR4 is involved in the occurrence and development of various cancers. However, the effect of BCAR4 on CRC chemotherapy resistance remains unclear.
Methods
Real-time quantitative PCR and Western blotting were used to detect the expression levels of gene and protein, respectively. The role of BCAR4 in drug resistance was evaluated by cell viability and apoptosis experiments. Luciferase reporter assay and Western blot analysis confirmed the relationship between BCAR4, miR-483-3p, and RAB5C.
Results
Luciferase reporter assay and Western blotting analysis confirmed the relationship among BCAR4, miR-483-3p, and RAB5C. The results showed that the expression levels of BCAR4 and RAB5C were increased in CRC tumor tissue. The expression levels of BCAR4 were increased in patients with chemotherapy resistance. Functional analysis showed that knockdown of BCAR4 reduced the expression levels of proteins related to stemness, decreased the activity of cells, and promoted apoptosis of CRC cells, while overexpression of RAB5C reversed these effects. Moreover, the results showed that BCAR4 promoted oxaliplatin resistance by inhibiting cell apoptosis. Mechanistically, BCAR4 sponged miR-483-3p and promoted the expression of RAB5C. Knockdown of BCAR4 reduced tumor size and enhanced cell sensitivity to oxaliplatin in vivo.
Conclusion
The results suggested that BCAR4/miR-483-3p/RAB5C axis has the potential to be explored as a novel therapeutic target for CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zitieren
APA
Li, X., Chen, X., Fu, C., Xie, M., & Ouyang, S. (2023). Long Non-Coding RNA BCAR4 Promotes Oxaliplatin Resistance in Colorectal Cancer by Modulating miR-484-3p/RAB5C Expression. Chemotherapy, 68(3), 119-130. https://doi.org/10.1159/000529134
Vancouver
Li X, Chen X, Fu C, Xie M, Ouyang S. Long Non-Coding RNA BCAR4 Promotes Oxaliplatin Resistance in Colorectal Cancer by Modulating miR-484-3p/RAB5C Expression. Chemotherapy. 2023;68(3):119-130. doi:10.1159/000529134
BibTeX
@article{Li2023,
author = {Li, Xianting and Chen, Xiaojiao and Fu, Chendong and Xie, Ming and Ouyang, Shurui},
title = {Long Non-Coding RNA BCAR4 Promotes Oxaliplatin Resistance in Colorectal Cancer by Modulating miR-484-3p/RAB5C Expression},
journal = {Chemotherapy},
year = {2023},
volume = {68},
number = {3},
pages = {119--130},
doi = {10.1159/000529134}
}
EUVIMED